Compare Open Text Corporation (OTEX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Open Text Corporation vs Summit Therapeutics Inc — how do they compare? Open Text Corporation trades at $22.41 (market cap $5.54B), while Summit Therapeutics Inc trades at $14.78 (market cap $11.34B). The key difference: Summit Therapeutics Inc is far larger — about 2× Open Text Corporation's market cap, and Open Text Corporation pays a 4.83% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| OTEX | SMMT | |
|---|---|---|
Market Cap | $5.54B | $11.34B |
Sector | Technology | Health |
52-Week High | $39.69 | $29.32 |
52-Week Low | $20.01 | $13.05 |
Enterprise Value | $10.70B | $10.76B |
Dividend Yield | 4.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Open Text Corporation (OTEX) trades at $23.33, up 0.26% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.01 surpassing expectations. Fundamentals show a P/E of 11.32 and net income margin of 9.91%, while recent news highlights a $105 million investment in European AI and cloud expansion.
The outlook for OTEX is positive, supported by value-oriented valuation, consistent earnings outperformance, and strategic investments in AI. Key risks include competitive pressures in software and execution of growth initiatives. Analyst consensus suggests a 30.7% upside to the $29.75 price target, with 42% of ratings being Buy.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
